Skip to main content
Nyxoah SA logo

Nyxoah SA — Investor Relations & Filings

Ticker · NYXH ISIN · BE0974358906 LEI · 5493002O1ESKZ18OXR80 BR Manufacturing
Open in API
Filings indexed 563 across all filing types
Latest filing 2025-12-29 Major Shareholding Noti…
Country BE Belgium
Listing BR NYXH

About Nyxoah SA

https://www.nyxoah.com/

Nyxoah SA is a medical technology company focused on the development and commercialization of solutions for Obstructive Sleep Apnea (OSA). The company's lead product is the Genio® system, a hypoglossal neurostimulation (HNS) therapy designed for patients with moderate to severe OSA. The system features a patient-centered, leadless, and battery-free implantable stimulator. It functions by providing bilateral stimulation to the hypoglossal nerve, which controls tongue muscles, to maintain an open airway during sleep.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2025
Major Shareholding Notification
2025-12-29 English
FORM 6-K
Foreign Filer Report
2025-12-19 English
ENGLISH_Nyxoah SA - Press release First Tranche Bonds (ENG) (final).pdf
Capital/Financing Update Classification · 1% confidence The document is a press release issued by Nyxoah SA announcing the closing of the first tranche of a convertible bond financing agreement. It details the terms of the bonds, the use of proceeds, and the impact on the company's cash runway. Since this is a direct announcement of a financing activity (issuance of convertible bonds) rather than a periodic financial report or a simple notice of publication, it falls under the 'Capital/Financing Update' category.
2025-12-18 English
FRENCH_Nyxoah SA - Press Release First Tranche Bonds (FR) (final).pdf
Capital/Financing Update Classification · 1% confidence The document is a press release issued by Nyxoah SA announcing the issuance of the first tranche of convertible bonds. It details the financial terms, interest rates, conversion options, and the intended use of proceeds. This type of announcement regarding fundraising and capital structure changes falls under the 'Capital/Financing Update' category. It is not a full report, but rather a corporate announcement of a specific financing event.
2025-12-18 French
Project Neurone - EY Report (Convertible) (signed).pdf
Capital/Financing Update Classification · 1% confidence The document is an auditor's report (Rapport d'évaluation) issued by EY regarding financial and accounting data related to a capital increase and the issuance of convertible bonds by Nyxoah SA. It specifically references articles 7:180, 7:191, and 7:193 of the Belgian Code of Companies and Associations. Since this is a standalone audit/evaluation report concerning a specific corporate action (capital increase) rather than a full annual report or a general regulatory announcement, it falls under the 'Audit Report / Information' category.
2025-12-18 French
Project Neurone - Special Board Report (Convertible) (ENG) (signed) (INCL T&C).pdf
Capital/Financing Update Classification · 1% confidence The document is a 'Special Report of the Board of Directors' regarding the issuance of convertible bonds and the cancellation of preferential subscription rights. It details the legal basis (Belgian Code on Companies and Associations), the structure of the transaction (tranches, subscription agreements), and the justification for the capital action. This is a formal corporate governance and capital structure document, which falls under the category of 'Capital/Financing Update' as it describes the issuance of securities and financing activities.
2025-12-18 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.